-transparent.png){kind=logo}
The Clinical Trials Group of the National Cancer Institute of Canada (NCIC) studied single-agent epirubicin in 40 previously untreated patients with extensive small-cell lung cancer (SCLC). The starting dose of epirubicin was 100 (eight patients) or 120 (32 patients) mg/m2 administered intravenously every 3 weeks. Twenty patients (50%) achieved an objective response (95% confidence limits, 33% to 66%) and three of the 20 had complete responses (CRs). The median survival of all 40 patients was 8.3 months (35.4 weeks). Myelosuppression, mild or moderate nausea and vomiting, and hair loss were commonly seen. There was one chemotherapy-related death. This drug is active and well tolerated in SCLC and the use of it as first-line therapy did not appear to compromise survival in this group of patients.
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
October 1988,
British journal of cancer,
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
March 1994,
Annals of oncology : official journal of the European Society for Medical Oncology,
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
January 1992,
European journal of cancer (Oxford, England : 1990),
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
November 1996,
Lung cancer (Amsterdam, Netherlands),
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
March 1996,
Annals of oncology : official journal of the European Society for Medical Oncology,
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
January 1996,
Investigational new drugs,
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
August 1990,
Investigational new drugs,
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
January 1997,
Investigational new drugs,
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
January 1990,
Investigational new drugs,
M Blackstein, and
E A Eisenhauer, and
R Wierzbicki, and
S Yoshida
August 1986,
Cancer treatment reports,
